Chemotherapy Strategies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Eileen O’Reilly, MD
Efrat Dotan, MD
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
Fernando López-Ríos, MD, PhD
Christian Rolfo, MD, PhD
Charlie Gourley, MD, PhD
From Guidelines to Practice: First-Line Treatment Choices in mCRC
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Collaborative Insights to Solve the Puzzle of Bladder Cancer
Daniel P. Petrylak, MD
Elizabeth R. Plimack, MD, MS, FASCO
Evan Y. Yu, MD
Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer
Understanding the Expanding Role of Antibody-Drug Conjugates in Bladder Cancer
Lillibeth Velasco, MSN, RN
Patient Perspectives on Bladder Cancer
Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
Javier Cortes, MD, PhD
Hope S. Rugo, MD, FASCO
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
Molecular Profiling for HER2+ Advanced Solid Tumors
Eric Van Cutsem, MD, PhD
David SP Tan, MBBS, PhD, PRCP
James Chih-Hsin Yang, MD, PhD
Kathleen Moore, MD, MS, FASCO
Diagnosis and Management of Metastatic PDAC
Shubham Pant, MD, MBBS
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
Sara Lonardi, MD
The Evolving Treatment Landscape for MBC: Emerging Therapies
William J. Gradishar, MD
Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
Alan Venook, MD
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
Aparna R. Parikh, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.